S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:JSPR

Jasper Therapeutics Stock Forecast, Price & News

$11.49
-1.76 (-13.28 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.31
$12.94
50-Day Range N/A
52-Week Range
$7.11
$18.88
Volume766,583 shs
Average Volume913,290 shs
Market Capitalization$143.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
30 days | 90 days | 365 days | Advanced Chart
Receive JSPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Jasper Therapeutics

Amplitude Healthcare Acquisition Corporation entered into a definitive business combination agreement with Jasper Therapeutics Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JSPR
Web
N/A
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.40 per share

Profitability

Net Income
$-590,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$143.63 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

407th out of 1,358 stocks

Biological Products, Except Diagnostic Industry

59th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Jasper Therapeutics (NASDAQ:JSPR) Frequently Asked Questions

Is Jasper Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jasper Therapeutics stock.
View analyst ratings for Jasper Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Jasper Therapeutics?

Wall Street analysts have given Jasper Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Jasper Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for JSPR?

3 Wall Street analysts have issued 12 month price objectives for Jasper Therapeutics' shares. Their forecasts range from $19.00 to $21.00. On average, they expect Jasper Therapeutics' share price to reach $20.00 in the next year. This suggests a possible upside of 74.1% from the stock's current price.
View analysts' price targets for Jasper Therapeutics
or view top-rated stocks among Wall Street analysts.

What is Jasper Therapeutics' stock symbol?

Jasper Therapeutics trades on the NASDAQ under the ticker symbol "JSPR."

How do I buy shares of Jasper Therapeutics?

Shares of JSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jasper Therapeutics' stock price today?

One share of JSPR stock can currently be purchased for approximately $11.49.

How much money does Jasper Therapeutics make?

Jasper Therapeutics has a market capitalization of $143.63 million.

How many employees does Jasper Therapeutics have?

Jasper Therapeutics employs 3 workers across the globe.

Where are Jasper Therapeutics' headquarters?

Jasper Therapeutics is headquartered at 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036.

How can I contact Jasper Therapeutics?

Jasper Therapeutics' mailing address is 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036. The company can be reached via phone at 212-823-1900.


This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.